Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR‐T and TCR‐T Cell Therapies: An Industry Perspective

Hardik Mody(Kaiser Permanente South San Francisco Medical Center), Vijay Upreti(Amgen (United States)), Jochem Gokemeijer(Bristol-Myers Squibb (Germany)), Nagendra Chemuturi(Moderna Therapeutics (United States)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Prathap Nagaraja Shastri(Springhouse), Sreeneeranj Kasichayanula(Gilead Sciences (United States)), Michael Z. Liao(Kaiser Permanente South San Francisco Medical Center), K. OGASAWARA(Bristol-Myers Squibb (United States)), Dale Miles(Kaiser Permanente South San Francisco Medical Center), Tong‐Yuan Yang(Janssen (United States)), Xu Zhu(AstraZeneca (Brazil)), Swati Gupta(AbbVie (United States))
Clinical Pharmacology & Therapeutics
July 2, 2023
10.1002/cpt.2986
Cited by 26

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
|Molecular Therapy — Methods & Clinical Development|2022|113
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
|Journal of Clinical Oncology|2023|94
2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene &amp; Cell Therapy and Vaccine Assays)
|Bioanalysis|2021|60
Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays
|mAbs|2021|57
2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)
|Bioanalysis|2018|53